The Onco'Zine Brief

In this episode of The Onco'Zine Brief Peter Hofland and Sonia Portillo talk with Alice Crisci.

Alice is a cancer survivor.

As part of her journey to survival Crisci founded Fertile Action, a cancer charity established to ensure fertile people touched by cancer can become mothers. As a cancer survivor and a single mom who faced issues of infertility, Alice dealt with the challenges of figuring out how preserve her fertility so that one day she could have a child.

Alice own need resulted in the founding of a non-profit organization – Fertile Acton – which provides Education and Advocacy, offering empowering education to patients and physicians, and help oncologists have specific fertility conversation with patients during the treatment planning phase

Crisci founded Fertile Action a few weeks after she was diagnosed with breast cancer. At that time she was just 31-years-old.

Crisci also launched MedAnswers, a digital health app that connects anonymous patients, to board certified experts in various medical disciplines for personalized question and answer sessions.

Become a supporter of this podcast: https://www.spreaker.com/podcast/the-onco-zine-brief--2786156/support.

Each year, 1.4 million people are diagnosed with lung cancer worldwide. The 5-year survival rate for these patients is only 15.9%.

In this episode of the Peter Hofland and Sonia Portillo, the team behind The Onco'Zine Brief, interview Bonnie Adario, Cancer Survivor.

Addario was was first diagnosed with stage 3b lung cancer in 2004, a cancer with a survival rate of only 5%. As part of her treatment, Addario underwent surgery to remove one lobe, radiation and chemotherapy treatments, and, against the odds, became a lung cancer survivor.

After this experience, she felt an urgent need to impact lung cancer care in a big way.

In 2006, she started the Bonnie J. Addario Lung Cancer Foundation, now one of the largest philanthropies that is exclusively dedicated to lung cancer.

The foundation Addario set up has the goal of working with a diverse group of physician’s organization, industry partners, patients and survivors in efforts to find solutions and make meaningful changes in lung cancer, and they hope to turn lung cancer into a chronically managed disease by 2023.

Addario's foundation manages several projects, some in collaboration with the Addario Lung Cancer Medical Institute – an international non-profit research consortium.

This research consortium, also called ‘Alchmey’, directly facilitates collaboration between investigators from over 22 institutions in the United States and Europe, and is supported by research infrastructures including centralized tissue banks and data systems.

They also combine the expertise of scientific and medical professionals with patient’s access through a network of community cancer centers.

This helps to accelerate research and advance ongoing projects from both the foundation and the medical institute.

In this interview, Addario shares with some inside perspectives on where we are with lung cancer treatment, as well as some of the exciting projects being developed by her team at the Bonnie J. Addario Lung Cancer Foundation.

Become a supporter of this podcast: https://www.spreaker.com/podcast/the-onco-zine-brief--2786156/support.

In this episode of The Onco'Zine Brief, Peter Hofland and Sonia Portillo, talk with David R. Epstein B.Sc, MBA, the Executive Chairman of Rubius Therapeutics.

Epstein explains how his company is pioneering novel Red-Cell Therapeutics or RCTs – nicknamed ‘superblood’ – as a new class of medicines to address a wide array of diseases.

He explains how these novel drugs have leading applications in cancer, rare and autoimmune disease, as well as additional potential in hemophilia, infectious and metabolic diseases.

Become a supporter of this podcast: https://www.spreaker.com/podcast/the-onco-zine-brief--2786156/support.

Lung cancer remains one of the most frequently diagnosed cancers. It is also one of the deadliest cancers – with each year more than 1.6 million tumor-related deaths worldwide.

The correlation between smoking and mortality from lung cancer has been clearly confirmed and a decrease of mortality after cessation of tobacco use has been seen in the United States. Since the 1990s first in men and later, since the early 2000s also in women.

Although direct environmental exposure to tobacco smoke is the predominant risk factor, inhalation of cancer causing agents such as marijuana or hookah us also contributes to the risk of lung cancer.

Additional risk factors include exposure to radon, asbestos, diesel exhaust and ionizing radiation. Furthermore, the latest evidence suggests that there is a correlation between lung cancer and chronic obstructive lung disease that is independent of tobacco use and is most likely caused as a result of a genetic abnormality.

In this episode of The Onco'Zine Brief Peter Hofland and Sonia Portillo interview Fred R. Hirsch, MD, PhD, Chief Executive Officer of International Association for the Study of Lung Cancer (IASLC) and a professor at the University of Colorado School of Medicine.

They discuss new treatment options for patients with lung cancer.

Become a supporter of this podcast: https://www.spreaker.com/podcast/the-onco-zine-brief--2786156/support.

In this episode of The Onco'Zine Brief, Peter Hofland and Sonia Portillo talk with Robert Z. Orlowski, MD, PhD, chairman, Ad Interim, Director of Myeloma and Professor of Medicine in the Departments of Lymphoma, Myeloma and Experimental Therapeutics in the Division of Cancer Medicine at MD Anderson in Houston, Texas.

They ask Orlowski about his thoughts and unique perspective on research and the recent advancements in the treatment multiple myeloma (a type of blood cancer), including promising results with a drug called carfilzomib (marketed as Kyprolis® by Amgen), which has become the first treatment proven to extend the overall survival of patients with relapsed multiple myeloma when compared to the current standard of care.

In healthy people, normal plasma cells are found in the bone marrow and are an important part of the immune system. In patients with multiple myeloma, these cells have become malignant. These malignant plasma cells accumulate in the bone marrow, crowding out the normal plasma cells that help fight infections.

Become a supporter of this podcast: https://www.spreaker.com/podcast/the-onco-zine-brief--2786156/support.

In this episode of The Onco'Zine Brief, recorded during CPhI World Wide, held October 24 - 27, 2017 in Frankfurt, Germany, Peter Hofland and Sonia Portillo, interview Charlie Johnson, the CEO of ADC Bio.

ADC Bio, a biotechnology company developing new process technology to speed, simplify and significantly lower the production costs of the latest generation of novel anti-cancer blockbuster drugs known as Antibody-drug Conjugates or ADCs.

Antibody-drug Conjugates are a new class of highly potent biopharmaceutical drugs composed of an antibody linked, via a chemical linker, to a biologically active drug or cytotoxic compound. These novel, targeted agents combine the unique and very sensitive targeting capabilities of antibodies allowing sensitive discrimination between healthy and cancer tissues with the cell-killing ability of cytotoxic drugs.

Become a supporter of this podcast: https://www.spreaker.com/podcast/the-onco-zine-brief--2786156/support.

Even modest use of alcohol may increase cancer risk. The greatest risks are observed with heavy, long-term use of alcohol. Now, for the first time, the American Society of Clinical Oncology (ASCO) has formally recognized that alcohol drinking is a risk factor for multiple malignancies. This risk is, however, potentially modifiable.

Become a supporter of this podcast: https://www.spreaker.com/podcast/the-onco-zine-brief--2786156/support.